"Speaking the dialect": Understanding public discourse in the aftermath of an HIV vaccine trial shutdown

American Journal of Public Health

Volumn 101, Issue 9, 2011, Pages 1749-1758

  Newman, Peter A ^a   Logie, Carmen ^a   James, LLana ^b   Charles, Tamicka ^c   Maxwell, John ^d   Salam, Khaled ^e   Woodford, Michael ^f  

^a UNIVERSITY OF TORONTO   (Canada)

^b Women's Health in Women's Hands Community Health Centre   (Canada)

^c Streetlight Support Services   (Canada)

^d AIDS Committee of Toronto ^*  (Canada)

^e AIDS Committee of Ottawa   (Canada)

^f UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; AGED; ARTICLE; CANADA; ETHNIC GROUP; FEMALE; HIGH RISK BEHAVIOR; HUMAN; INFORMATION PROCESSING; MALE; METHODOLOGY; MIDDLE AGED; PARTICIPATORY RESEARCH; PROSTITUTION; PSYCHOLOGICAL ASPECT; QUALITATIVE RESEARCH; SEX DIFFERENCE; SEXUALITY; STATISTICS; SUBSTANCE ABUSE; URBAN POPULATION;

ADULT; AGED; AIDS VACCINES; CANADA; COMMUNITY-BASED PARTICIPATORY RESEARCH; ETHNIC GROUPS; FEMALE; FOCUS GROUPS; HUMANS; MALE; MIDDLE AGED; PROSTITUTION; QUALITATIVE RESEARCH; RESEARCH DESIGN; RISK-TAKING; SEX FACTORS; SEXUALITY; SUBSTANCE ABUSE, INTRAVENOUS; URBAN POPULATION;

EID: 80052007889     PISSN: 00900036     EISSN: 15410048     Source Type: Journal    
DOI: 10.2105/AJPH.2011.300208     Document Type: Article

References (40)

1. Belshe R, Franchini G, Girard MP, et al. Support for the RV144 HIV vaccine trial. Science. 2004;305(5681): 177-180.
2. Burton DR, Desrosiers RC, Doms RW, et al. Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science. 2004;303(5656):316. (Pubitemid 38095757)
3. Fauci AS, Johnston MI, Dieffenbach CW, et al. HIV vaccine research: the way forward. Science. 2008; 321(5888):530-532.
4. Khanlou H, Weinstein M. Enough is enough: instead of continuing to squander hundreds of millions of dollars on a futile quest for an HIV vaccine, focus AIDS spending on prevention, testing and treatment. AIDS Healthcare Foundation. March 23, 2008. Available at: http://www.increaseaidsfunding.ca/ docs/baltimoresun-032308.pdf. Accessed February 4, 2011.
5. Leavy O. HIV vaccine results controversy. Nat Rev Immunol. 2009;9(11):755.
6. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med. 2009;361(23):2209-2220.
7. Watanabe ME. Skeptical scientists skewer VaxGen statistics. Nat Med. 2003;9(4):376. (Pubitemid 36460053)
8. Singh JA, Mills EJ. The abandoned trials of pre-exposure prophylaxis for HIV: what went wrong? PLoS Med. 2005;2(9):e234.
9. Newman PA. Towards a science of community engagement. Lancet. 2006;367(9507):302.
10. Newman PA, Duan N, Kakinami L, Roberts KJ. What can HIV vaccine trials teach us about dissemination? Vaccine. 2008;26(20):2528-2536.
11. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet. 2008; 372(9653):1881-1893.
12. Corey L, McElrath MJ, Kublin JG. Post-step modifications for research on HIV vaccines. AIDS. 2009;23(1): 3-8.
13. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med. 2008;205(1):7-12.
14. Watkins DI, Burton DR, Kallas EG, Moore JP, Koff WC. Nonhuman primate models and the failure of the Merck HIV-1 vaccine in humans. Nat Med. 2008;14(6): 617-621. (Pubitemid 351809543)
15. van Dijk TA. Analyzing racism through discourse analysis. Some methodological reflections. In: Stanfield JH, Dennis RM, eds. Race and Ethnicity in Research Methods: Newbury Park, CA: Sage Publications; 1993: 92-134.
16. Roth WD, Mehta JD. The Rashomon effect: combining positivist and interpretivist approaches in the analysis of contested events. Sociol Methods Res. 2002; 31(2):131-173. (Pubitemid 36714497)
17. Fischhoff B, Bostrom A, Quadrel MJ. Risk perception and communication. Annu Rev Public Health. 1993;14: 183-203. (Pubitemid 23161717)
18. Morgan GM, Fischhoff B, Bostrom A, Atman CJ. Risk Communication: A Mental Models Approach. Cambridge, UK: Cambridge University Press; 2002.
19. Slovic P. Trust, emotion, sex, politics and science: surveying the risk-assessment battlefield. Risk Anal. 1999;19(4):689-701.
20. Dhalla S, Nelson K, Singer J, Poole G. HIV vaccine preparedness studies in the non-Organization for Economic Co-operation and Development (non-OECD) countries. AIDS Care. 2009;21(3):335-348.
21. Mills E, Cooper C, Guyatt G, et al. Barriers to participating in an HIV vaccine trial: a systematic review. AIDS. 2004;18(17):2235-2242. (Pubitemid 39620215)
22. Newman PA, Duan N, Roberts KJ, et al. HIV vaccine trial participation among ethnic minority communities. J Acquir Immune Defic Syndr. 2006;41(2):210-217.
23. Strauss AL, Corbin JM. Basics of Qualitative Research: Techniques And Procedures for Developing Grounded Theory. 4th ed. Thousand Oaks, CA: Sage Publications; 1998.
24. Israel BA, Schulz AJ, Parker EA, Becker AB. Review of community-based research: assessing partnership approaches to improve public health. Annu Rev Public Health. 1998;19:173-202. (Pubitemid 28279929)
25. Statistics Canada. Canada's population clock. November 18, 2010. Available at: http://www.statcan.gc.ca/ig-gi/pop-ca-eng.htm. Accessed February 4, 2011.
26. Public Health Agency of Canada, Surveillance and Risk Assessment Division, Centre for Communicable Diseases and Infection Control. HIV and AIDS in Canada: surveillance report to December 31, 2008. Available at: http://www.phac-aspc.gc.ca/aids-sida/publication/survreport/2008/dec/pdf/ survrepdec08.pdf. Accessed February 4, 2011.
27. Remis RS, Swantee C, Liu J. Report on HIV/AIDS in Ontario 2008. Ontario Ministry of Health and Long-Term Care. April, 2010. Available at: http://www.phs.utoronto.ca/ohemu/doc/PHERO2008-report-final.pdf. Accessed February 4, 2011.
28. Charmaz K. Constructing Grounded Theory: A Practical Guide Through Qualitative Analysis. Thousand Oaks, CA: Sage Publications; 2006.
29. Glaser BG. Doing Grounded Theory: Issues and Discussions. Mill Valley, CA: Sociology Press; 1998.
30. Kuper A, Reeves S, Levinson W. An introduction to reading and appraising qualitative research. BMJ. 2008; 337:a288.
31. Newman PA, Seiden DS, Roberts KJ, Kakinami L, Duan N. A small dose of HIV? HIV vaccine mental models and risk communication. Health Educ Behav. 2009;36(2):321-333.
32. Global Campaign for Microbicides. About microbicides. 2009. Available at: http://www.global-campaign.org/about-microbicides.htm. Accessed February 4, 2011.
33. UNAIDS. The UN declaration of commitment and people living with HIV/AIDS PWAs. 2001. Available at: http://data.unaids.org/pub/BaseDocument/2007/ gipa2001un-en.pdf. 2001. Accessed February 4, 2011.
34. Adam BD, Elliott R, Husbands W, Murray J, Maxwell J. Effects of the criminalization of HIV transmission in Cuerrier on men reporting unprotected sex with men. Can J Law Soc. 2008;23(1-2):143-159.
35. Newman PA, Yim S, Daley A, et al. "Once bitten, twice shy": volunteer perspectives in the aftermath of an early HIV vaccine trial termination. Vaccine. 2011;29(3): 451-458.
36. Kalichman SC. Denying AIDS: Conspiracy Theories, Pseudoscience, and Human Tragedy. New York, NY: Springer; 2009.
37. Jacobson RM, Targonski PV, Poland GA. A taxonomy of reasoning flaws in the anti-vaccine movement. Vaccine. 2007;25(16):3146-3152. (Pubitemid 46482757)
38. Marlow LAV, Forster AS, Wardle J, Waller J. Mothers' and adolescents' beliefs about risk compensation following HPV vaccination. J Adolesc Health. 2009; 44(5):446-451.
39. Human Papillomavirus HPV Vaccination Program Update. Toronto, Ontario, Canada: Medical Officer of Health; 2008. Available at: http://www.toronto.ca/ legdocs/mmis/2008/hl/bgrd/backgroundfile-15460. pdf. Accessed February 4, 2011.
40. Koff WC, Berkley SF. The renaissance in HIV vaccine development-future directions. N Engl J Med. 2010;363(5):e7.